Kisspeptin-10 10mg — KP-10 GPR54/GnRH Activator

Zoom

34,00 €

Tax included • Free delivery from 99€

Almost sold out, alert me on restock

Kisspeptin-10 10mg (KP-10, Metastin 45-54) is a decapeptide with the sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2, corresponding to the bioactive C-terminal fragment of native kisspeptin-54 encoded by the human KISS1 gene on chromosome 1q32. With a molecular weight of approximately 1302 Da, this synthetic decapeptide binds to the G protein-coupled receptor GPR54 (renamed KISS1R) with nanomolar affinity and constitutes today one of the most precise pharmacological tools to study the human hypothalamic-pituitary-gonadal axis.

KP-10 occupies an absolutely central position in reproductive endocrinology. Kisspeptinergic neurons in the arcuate (ARC) and anteroventral periventricular (AVPV) hypothalamic nuclei control pulsatile release of gonadotropin-releasing hormone (GnRH), which itself commands pituitary LH and FSH secretion, and ultimately gonadal function. Seminal work by Seminara and colleagues (2003, New England Journal of Medicine) and de Roux and colleagues (2003, PNAS) demonstrated that inactivating GPR54 mutations cause congenital hypogonadotropic hypogonadism with absent puberty, while activating mutations cause central precocious puberty. These discoveries established kisspeptin as the molecular gatekeeper of puberty and reproductive function.

The name's history is singular. Kisspeptin was initially discovered in 1996 by Jung-Hoon Lee and colleagues (Journal of the National Cancer Institute) as a metastatic suppressor of cancer, in the city of Hershey, Pennsylvania, hence the nod to Hershey's Kisses chocolates and the name "kisspeptin". It was only in 2001-2003 that its endocrine and reproductive role was revealed through discovery of its endogenous receptor GPR54 and first human studies.

In exploratory research, KP-10 distinguishes itself by unique pharmacological specificity: it selectively activates GPR54 without cross activity on other peptide receptors, generating clean and reproducible stimulation of the GnRH-LH-FSH axis. Each Atlas Lab vial ships lyophilized, with an HPLC specification of at least 98% purity. The short plasma half-life (approximately 4 minutes for KP-10 versus 27 minutes for native KP-54) imposes an IV bolus or SC administration protocol with frequent rotations, typical of clinical endocrinology explorations.

Science

01
Mechanism of action

Kisspeptin-10 mechanism of action articulates a hierarchical neuroendocrine cascade of rare elegance, where activation of a single hypothalamic GPR54 receptor triggers the entire human reproductive axis within minutes.

First stage, GPR54 activation on GnRH neurons. GPR54 (KISS1R) is a Class A G protein-coupled receptor, predominantly expressed on GnRH neurons of the preoptic hypothalamus. KP-10 binding activates the Gq/11 -> phospholipase C beta -> IP3 production -> calcium release from reticular stores pathway. This intraneuronal calcium elevation triggers synaptic vesicle fusion containing GnRH and pulsatile release of the neuropeptide into the hypothalamic-pituitary portal system. The effect is rapid: GnRH release is detectable within 5 minutes after KP-10 IV administration, with peak at 15-30 minutes.

Second stage, pituitary stimulation. Released GnRH activates GnRH-R receptors on anterior pituitary gonadotropes, triggering secretion of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone). In healthy adult men, a single 0.3 mcg/kg IV dose of KP-10 produces robust and reproducible serum LH elevation of 3 to 8 times baseline within 30 minutes, with more modest and prolonged FSH elevation (Dhillo and colleagues 2005, JCEM).

Third stage, gonadal action. LH elevation stimulates testicular Leydig cells producing testosterone and activates ovarian thecal cells involved in steroidogenesis. FSH elevation supports spermatogenesis in men and follicular maturation in women. The testosterone effect in men is measurable 4 to 6 hours after single administration, with 20-to-50-percent increase in serum testosterone in healthy subjects.

Fourth axis, duality of kisspeptinergic neuronal populations. Kisspeptin neurons of the arcuate nucleus (ARC) co-express neurokinin B and dynorphin (KNDy population) and are responsible for baseline GnRH pulsatility in both sexes. AVPV neurons predominate in females and mediate the preovulatory LH surge in response to estrogen positive feedback. This duality explains why KP-10 can be used both to study baseline GnRH pulsatility and to trigger ovulation (Abbara 2015 JCEM).

Fifth dimension, extra-hypothalamic action. KP-10 also exerts documented extra-gonadal axis effects. At the limbic brain level, Comninos and colleagues (2017, Journal of Clinical Investigation) showed by fMRI that KP-10 activates regions responsible for sexual emotional processing (insula, anterior cingulate gyrus, amygdala, hippocampus) in healthy men, with correlated improvement of sexual motivation parameters. Thurston and colleagues (2022, JAMA Network Open) extended these observations to men with HSDD. KP-10 also activates kisspeptin receptors expressed in placenta, trophoblastic vessels, and several cancers, but these actions fall outside the direct reproductive framework.

Clinical data

02Clinical studies

Scientific literature on Kisspeptin is particularly rich and of high academic level, with over 3,000 peer-reviewed publications since 2003 and human clinical trials published in top-tier journals (NEJM, JCI, JCEM, Nature, Cell). This scientific density distinguishes KP-10 from most exploratory research peptides and makes it one of the best characterized tools in modern reproductive endocrinology.

Founding discoveries: Lee and colleagues (1996, Journal of the National Cancer Institute, 88:23) identified the KISS1 gene as a metastatic suppressor, first on melanomas. Ohtaki and colleagues (2001, Nature, 411) characterized metastin/KP-54 as the endogenous GPR54 ligand. Then simultaneous publications by Seminara and colleagues (2003, NEJM, 349:17) and de Roux and colleagues (2003, PNAS, 100:19) demonstrated in human genetics that inactivating GPR54 mutations cause idiopathic hypogonadotropic hypogonadism, revolutionizing understanding of puberty and fertility.

First human KP-10 studies: Dhillo and colleagues (2005, JCEM, 90:12 pages 6609-6615) conducted the first IV KP-10 study in 6 healthy male volunteers, documenting significant dose-dependent increase in LH, FSH, and testosterone after infusion at 4 pmol/kg/min for 90 minutes. This seminal study established KP-10 as a human gonadal axis activator and paved the way for clinical applications.

Dhillo and colleagues (2007, JCEM, 92:10 pages 3958-3966) extended observations to healthy female volunteers in follicular, luteal, and preovulatory phases, confirming KP-10 effect dependence on menstrual cycle with maximal response in preovulatory phase. These results established KP-10 as a precise endocrine phenotyping tool.

Exploratory therapeutic applications: Jayasena and colleagues (2014, Journal of Clinical Investigation, 124:8 pages 3667-3677) demonstrated that KP-54 administration (longer-half-life variant) for 2 weeks restores LH pulsatility in women with functional hypothalamic amenorrhea, opening the way for treatment of infertility secondary to eating disorders and chronic stress.

Abbara and colleagues (2015, JCEM, 100:9 pages 3322-3331; and 2017 Human Reproduction) published pivotal studies demonstrating that KP-54 can trigger ovulation in IVF (in vitro fertilization) with efficacy equivalent to classical hCG but without risk of ovarian hyperstimulation syndrome (OHSS), the main dangerous complication of ovarian stimulation. This application could transform assisted reproductive safety if confirmed in phase III.

Neuro-sexual applications: Comninos and colleagues (2017, JCI, 127:2 pages 709-719) published the pivotal fMRI study demonstrating activation of sexual and emotional brain circuits by KP-10. Thurston and colleagues (2022, JAMA Network Open, 5:2) and Mills and colleagues (2023, Lancet Diabetes Endocrinol) conducted randomized clinical trials with KP-54 in men and women with hypoactive sexual desire disorder (HSDD), documenting significant improvement in desire and arousal scores, positioning kisspeptin as a potential competitor to Vyleesi (Bremelanotide) in this indication.

Integrative reviews: Kirby and colleagues (2010, J Neuroendocrinol), Skorupskaite and colleagues (2014, Hum Reprod Update), and Dhillo (2024, Nat Rev Endocrinol) published reference syntheses on the field, positioning kisspeptin as one of the major endocrinology discoveries of the 21st century and identifying application perspectives in infertility, hypogonadism, pubertal induction, sexual disorders, and functional endocrine diagnosis.

1
Axe HPGKisspeptin resets the hypothalamic GnRH clock in men
Chan YM, Butler JP, Pinnell NE, et al. · Journal of Clinical Endocrinology & Metabolism · 2011
2
ReproductionKisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males
Dhillo WS, Chaudhri OB, Patterson M, et al. · Journal of Clinical Endocrinology & Metabolism · 2005

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

The Atlas Lab Kisspeptin-10 10mg vial is reconstituted with 2 ml of bacteriostatic water to reach a final concentration of 5 mg/ml, or 5,000 mcg/ml. KP-10's very short plasma half-life (approximately 4 minutes) imposes specific administration protocols suited to endocrine explorations via bolus or continuous infusion, distinct from long-acting peptides.

Dhillo reference IV bolus protocol (pure endocrine research): the standard dose used in human literature is 0.3 mcg/kg IV bolus, approximately 20-25 mcg for a 70-80 kg adult, administered in 5 ml of physiological saline over 30 seconds. This dose produces robust and reproducible elevation of LH (x3 to x8 baseline within 30 minutes), FSH (modest prolonged elevation), and testosterone (+20-50% at 4-6 hours). IV administration is however poorly adapted to non-clinical exploratory use and remains reserved for equipped laboratories.

Exploratory subcutaneous protocol: in non-clinical exploratory research, subcutaneous administration of 50 to 200 mcg (0.01 to 0.04 ml of the 5 mg/ml reconstituted solution) offers acceptable bioavailability and prolonged kinetics through slow absorption from subcutaneous tissue. Administer in the morning upon waking to capture the physiological LH peak and maximize testosteronic response in men. Rotate injection sites (abdomen, thigh, deltoid) to avoid local irritations.

Continuous infusion protocol: phase II-III clinical studies (Jayasena 2014, Abbara 2015) use continuous SC or IV infusions of KP-54 or KP-10 over several hours or weeks. These protocols require dedicated infusion equipment and exit typical exploratory use. Short-half-life KP-10 requires higher flow rates than KP-54 to maintain stable plasma concentrations.

Administration frequency: KP-10 short half-life suggests daily or twice-daily administration in exploratory SC protocols. However, overly frequent administrations may induce GPR54 desensitization through receptor internalization, a phenomenon paradoxically responsible for using super-agonist GnRH analogs in oncology for chemical castration. Favor 5-to-10-day consecutive cycles followed by 5-to-10-day pauses to avoid this phenomenon and preserve receptor sensitivity.

Exploratory research indications: gonadal axis phenotyping (LH/FSH/testosterone response after single administration as functional test), male fertility evaluation (testosterone + spermiogram follow-up on 4-8-week protocols), modulation of libido and sexual desire (correlation with HSDD scores like FSFI or IIEF), ovulation induction in female models in strictly supervised context.

Absolute contraindications: pregnancy (robust gonadal axis activation), breastfeeding (insufficient data on milk passage), active or recently remitted hormone-dependent cancers (breast, prostate, endometrial, ovarian) due to testosteronic or estrogenic stimulation, severe hepatic or renal insufficiency. Caution in adolescents and pre-adolescents: KP-10 may trigger precocious puberty in subjects in pubertal maturation and should not be used outside strictly supervised medical protocols. Recommended biological monitoring: LH, FSH, total and bioavailable testosterone (men), estradiol, progesterone (women), baseline blood count and liver panel.

Reconstitution for this format (10 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
1 ml	10 mg/ml	10 UI = 1 mg
2 ml	5 mg/ml	40 UI = 2 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

The lyophilized Kisspeptin-10 10mg vial stores between 2 and 8 degrees Celsius in its original packaging, protected from direct light and any moisture source. Under these optimal conditions, a lyophilizate generally remains stable for up to 24 months. The lyophilized form is particularly sensitive to atmospheric humidity: systematically reseal the vial after handling and manipulate in controlled atmosphere. After reconstitution with 2 ml of bacteriostatic water (0.9% benzyl alcohol), the resulting 5 mg/ml solution shows moderate stability of 14 to 21 days between 2 and 8 degrees Celsius, appreciably shorter than for cyclic peptides like Melanotan-2 or PGP-stabilized heptapeptides like Semax or Selank. This shorter duration reflects the intrinsic sensitivity of the linear decapeptide to residual proteases and oxidation reactions on tyrosine, tryptophan, and serine residues. Plan vial usage accordingly: ideally, consume the reconstituted solution within 2 to 3 weeks maximum. Preserved stability by freezing: unlike most peptides, reconstituted KP-10 can be aliquoted in 0.5-to-1-ml fractions and stored at -20 degrees Celsius for extended duration up to 6 months with stability exceeding 90% measured by HPLC. This option is useful for users wanting to ration the vial across several spaced exploration cycles. Thaw each aliquot at refrigerated temperature and consume in one to two administrations to avoid any repeated freeze-thaw cycle. Upon reception, immediately place the vial in refrigeration. Brief exposure to ambient temperature during transport does not significantly alter lyophilized product bioactivity, but prolonging this exposure beyond 96 consecutive hours is inadvisable. Visual check before use: the reconstituted solution must remain perfectly clear, colorless, and free of visible particles. Any appearance of turbidity, precipitate, or intense yellow coloration indicates degradation and prohibits vial use. Linear decapeptides like KP-10 may develop visible fibrillary aggregates during prolonged solution storage, rendering the solution cloudy: in this case, discard the vial. Never dilute KP-10 with non-sterile water, solutions containing highly concentrated divalent metal ions, or heavily alkaline (above pH 9) or heavily acidic (below pH 3) buffered solutions. Dilutions in 0.9% NaCl, water for injection, and bacteriostatic water are compatible and recommended.

01What is the difference between Kisspeptin-10 and Kisspeptin-54?

Both molecules are fragments of the endogenous KISS1 peptide and both bind the GPR54 receptor with comparable potency. The fundamental difference is pharmacokinetics: KP-10 is a decapeptide with plasma half-life of approximately 4 minutes, while KP-54 is a 54-mer with half-life of approximately 27 minutes. This difference orients usage: KP-54 suits clinical protocols requiring prolonged stimulation (IVF ovulatory induction Abbara 2015, hypothalamic amenorrhea treatment Jayasena 2014 over several weeks), while KP-10 is preferred for occasional endocrine tests (LH/FSH profile after single bolus type Dhillo 2005) and brief explorations. Synthesis cost and accessibility favor KP-10 for non-clinical exploratory research.

02Can KP-10 increase testosterone in men?

Yes, in a documented and reproducible manner in men with functional gonadal axis. The Dhillo 2005 JCEM seminal study showed a 20-to-50-percent increase in total serum testosterone 4 to 6 hours after single IV administration of 0.3 mcg/kg KP-10, via the GPR54 -> GnRH -> LH -> Leydig -> testosterone cascade. This increase is physiological and transient, returning to baseline within 12 to 24 hours. In repeated protocols over several weeks, elevation is maintained but modest, without supra-physiologies observed with hCG gonadotropins. KP-10 only works if the hypothalamic-pituitary-gonadal axis is functional; it is ineffective in primary hypogonadism (Klinefelter, testicular insufficiency) and secondary hypogonadisms with mutant GPR54. Recommended monitoring: baseline and 4-6-week LH, FSH, total and bioavailable testosterone.

03Can KP-10 improve female fertility?

The most robust clinical data concern the KP-54 form rather than KP-10 for this indication. Jayasena 2014 JCI demonstrated that 2 weeks of KP-54 restore LH pulsatility in women with functional hypothalamic amenorrhea (secondary to chronic stress, weight loss, intense physical activity). Abbara 2015 JCEM and 2017 Human Reproduction showed that KP-54 can trigger ovulation in IVF with efficacy equivalent to classical hCG but WITHOUT risk of ovarian hyperstimulation syndrome (OHSS), the main dangerous complication of ovarian stimulation. KP-10 provides the same GPR54 action with shorter pharmacokinetics, less suited to prolonged clinical protocols. In exploratory female fertility research, KP-10 remains useful for functional phenotyping (LH/FSH response test) but KP-54 is preferable for therapeutic interventions.

04What side effects to expect with KP-10?

KP-10's tolerance profile is remarkably good in human clinical studies (Dhillo 2005/2007, Comninos 2017, Thurston 2022). Reported adverse effects are mainly linked to IV infusion itself (brief vaso-vagal reaction, fleeting heat sensation, mild nausea in less than 10% of subjects) and disappear within minutes. No significant cardiac, hepatic, or renal effect has been documented. Unlike melanocortins (MT-2, PT-141) that frequently produce nausea and intense flush, KP-10 is generally well tolerated. Potentially more marked side effects are hormonal: transient testosterone increase (which may aggravate acne in predisposed subjects), libidinal stimulation (sought or not), and theoretically risk of pubertal triggering in adolescents (hence the contraindication). Long-term effects of repeated protocols remain under-studied outside formal clinical trials.

05Can KP-10 improve libido and sexual desire?

Yes, solid fMRI and randomized clinical trial data. Comninos 2017 JCI showed by functional imaging that KP-10 activates limbic circuits responsible for sexual emotional processing (insula, anterior cingulate gyrus, amygdala, hippocampus) in healthy men, with correlated improvement in sexual motivation scores. Thurston 2022 JAMA Network Open extended these observations to men with hypoactive sexual desire disorder (HSDD) in a randomized placebo-controlled trial, documenting significant increase in desire and arousal scores measured by FSFI and dedicated questionnaires. Mills 2023 Lancet Diabetes Endocrinol confirmed in women with HSDD. KP-10 thus positions itself as an emerging alternative to Vyleesi (Bremelanotide) with different mechanism and potentially more favorable side effect profile (absence of melanocortin nausea and flush), at the cost of shorter pharmacokinetics and parenteral administration route.

06Why is Kisspeptin named this way?

The name "kisspeptin" comes from the city of Hershey in Pennsylvania, where the KISS1 gene was identified in 1996 by Jung-Hoon Lee and Danny Welch (Journal of the National Cancer Institute) as a metastatic suppressor of melanoma. In homage to the famous Hershey's Kisses chocolates produced in the same city, the discoverers named the gene KISS1 and the peptide "kisspeptin". It was only in 2001-2003 that Ohtaki and colleagues (Nature 2001), Muir and colleagues (Brain Research 2001), Kotani and colleagues (JBC 2001) identified the GPR54 receptor as endogenous target, and Seminara 2003 NEJM and de Roux 2003 PNAS revealed the central reproductive role of the system. The history is fairly unique in modern biomedicine: a fortuitous discovery of a cancer suppressor became one of the cornerstones of reproductive endocrinology 7 years later.

07Can KP-10 be used in adolescents or in cases of delayed puberty?

No, formally contraindicated in exploratory self-administration in minors and subjects with incomplete pubertal maturation. KP-10 may theoretically trigger precocious puberty through premature activation of the hypothalamic-pituitary-gonadal axis, and formal clinical trials have documented its use only within strict supervised medical protocols for idiopathic delayed puberty (Seminara 2003 NEJM suggests theoretical efficacy, subsequent clinical studies limited). Any exploration in an adolescent must be framed in a medical protocol with pediatric endocrinologist, complete prior hormonal assessment, pituitary imaging, and auxological follow-up. Non-medical exploratory use in minors exposes to risks of accelerated bone maturation (premature growth plate closure with reduction of final adult height), inadequate sexual development, and psychological effects of forced maturation. Reserve KP-10 for adults with already mature functional gonadal axis.

08Does KP-10 create tolerance or tachyphylaxis phenomenon?

Yes, documented and biologically expected. Continuous or overly frequent KP-10 administration causes GPR54 receptor desensitization through membrane internalization and receptor downregulation. This phenomenon is structurally identical to that observed with super-agonist GnRH analogs (leuprorelin, goserelin) and explains why these molecules are paradoxically used in oncology for chemical castration through prolonged pituitary desensitization. In exploratory research, this phenomenon imposes respecting cycles alternating 5 to 10 days of active administration and 5 to 10 days of pause to preserve receptor sensitivity. Clinical protocols frequently use pulsatile administration mimicking endogenous physiology (bolus every 2-3 hours) rather than continuous administration. In case of discontinuation after desensitization, GPR54 sensitivity is restored within 2 to 4 weeks, allowing a new effective cycle.

Benchmark

Similar peptides

Kisspeptin-10 positioning in the reproductive endocrinology space clarifies through systematic comparison with four major alternatives: Kisspeptin-54, GnRH analogs (gonadorelins), exogenous gonadotropins (hCG, hMG), and indirect gonadal axis modulators (clomiphene, anastrozole, enclomiphene).

Versus Kisspeptin-54 (KP-54, Metastin 68-121), KP-10 presents a different pharmacokinetic profile that influences use choice. KP-54 is a 54-amino-acid peptide with plasma half-life of approximately 27 minutes, markedly superior to KP-10's 4 minutes. This difference makes KP-54 more suited to clinical protocols requiring prolonged stimulation (ovulatory induction in IVF, treatment of hypothalamic amenorrhea over several weeks), while KP-10 is preferable for occasional endocrine tests (LH/FSH profile after single bolus) and brief explorations. Intrinsic GPR54 potency is comparable between the two forms, but synthesis cost and accessibility favor KP-10 for non-clinical exploratory research.

Versus GnRH analogs (gonadorelin, leuprorelin, goserelin), KP-10 acts one stage upstream in the neuroendocrine cascade. Exogenous GnRH directly stimulates pituitary gonadotropes, short-circuiting the hypothalamic step. This difference has a capital consequence: KP-10 only works in subjects whose hypothalamic GnRH axis is functional or reactivatable, while exogenous GnRH bypasses a potential hypothalamic lesion. Conversely, GnRH antagonists can theoretically block the pituitary effect of KP-10 without preventing hypothalamic GnRH release, providing a pharmacological dissection tool for the axis. GnRH agonists in continuous administration also produce pituitary desensitization sought in oncology, a profile that KP-10 may also present at repeated high doses.

Versus exogenous gonadotropins (hCG, hMG, recombinant FSH), KP-10 acts even further upstream and requires intact hypothalamic-pituitary-gonadal function. Exogenous gonadotropins directly stimulate gonads, bypassing the entire central axis, and are indispensable in cases of pituitary insufficiency or severe anovulation. KP-10 conversely offers the advantage of a more physiological hormonal profile, with maintenance of natural pulsatility and lower risk of iatrogenic hyperstimulation (OHSS in assisted reproductive medicine).

Versus indirect modulators like clomiphene (anti-estrogen hypothalamic agonist SERMs), enclomiphene (active stereoisomer), or anastrozole (aromatase inhibitor), KP-10 presents a fundamentally different mechanism. Clomiphene blocks hypothalamic estrogen receptors and thus lifts negative feedback, indirectly increasing endogenous GnRH secretion. KP-10 directly stimulates GnRH release without passing through this detour. The potential advantage of KP-10 is more reproducible action less dependent on sex and estrogenic status of the subject, but its short half-life and parenteral administration route limit its routine use versus oral SERMs.

The verdict: Kisspeptin-10 is the most direct tool to switch on the GnRH-LH-FSH axis, backed by solid published literature (Seminara NEJM 2003, Dhillo JCEM 2005, Comninos JCI 2017). HPLC specification of at least 98%. Plan biological monitoring (LH, FSH, testosterone, estradiol) and rule it out with a history of hormone-dependent cancer or during pregnancy.

Endocrinology

Product information

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents